Clinical Trials

Breast Neoplasms

NCT04697628 2026-02-24

innovaTV 301

502 enrolled 18 charts 1 FDA

Gynecologic

Uterine Cervical Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

400 enrolled

Breast Neoplasms, Recurrence

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06564844 2026-01-27

TROPION-Lung12

24 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

350 enrolled

Triple Negative Breast Neoplasms

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

300 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05347134 2025-12-09

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

254 enrolled

Triple Negative Breast Neoplasms

NCT06081959 2025-12-05

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06382142 2025-11-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

418 enrolled

Triple Negative Breast Neoplasms

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT06343948 2025-06-25

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

383 enrolled

HR+HER2- Breast Cancer

NCT06143553 2024-11-29

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

168 enrolled

Breast Neoplasms

NCT03191786 2024-10-23

IPSOS

453 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT03901339 2024-10-21

TROPiCS-02

543 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT05487391 2024-10-15

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

632 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02352948 2024-07-26

ARCTIC

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

NCT04400695 2024-01-24

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Phase 3 Unknown

366 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

420 enrolled

HER2-positive Advanced Breast Cancer

NCT02915744 2023-04-14

ATTAIN

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT02574455 2022-06-15

ASCENT

529 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02448797 2021-07-20

EVIDENCE

Phase 3 Unknown

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00054197 2020-10-05

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00088530 2020-02-05

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

140 enrolled 15 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT03811418 2019-11-26

ATTILA

Phase 3 Withdrawn

Tumor-Agnostic

Neoplasm Metastasis

NCT01125566 2019-07-18

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

508 enrolled 13 charts

Breast Neoplasms

NCT02225470 2018-08-28

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

530 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01007942 2017-04-05

BOLERO-3

569 enrolled 16 charts

Breast Neoplasms

NCT00683514 2016-10-04

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

201 enrolled

NSCLC

NCT00868634 2016-08-31

CARIN

600 enrolled

Breast Neoplasms

NCT00148798 2014-06-25

FLEX

1,861 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00055887 2013-05-10

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 3 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00042315 2012-05-23

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Terminated

490 enrolled